**6. Conclusion**

The burgeoning of the incidences of MBD is raising concern worldwide. Proper screening of the disorder is of prime importance in dealing with it. Although bisphosphonates remain the first-line treatment choice for the stated disorder, researchers should work upon the novel drugs with a unique mode of action and appreciable long-term safety profile. Based on the literature, it is pertinent to state that a fine balance between the non-pharmacological and pharmacological approaches could help out in dealing with MBD judiciously resulting in its prevention. Therefore, the battle for the search of better drugs for treating patients with metabolic bone diseases continues with an aim to provide better therapeutic efficacy and patient compliance.
